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Introduction
The glucose metabolism alterations present at both the cancer cell site and throughout the 
organism level in cancer patients are particularly evident in pancreatic ductal adenocarcinoma 
(PDAC), the fourth leading cause of cancer related deaths [1]. Glucose transporter GLUT1 
over expression at the cancer cell site favours the uptake of glucose, the main source for cellular 
energetics, on which in PET imaging the use of the tracer 18fluorodeoxyglucose is based [2]. In 
cancer cells glucose metabolism is reprogrammed and, even in the presence of oxygen, glucose is 
mainly processed in the cytosol to pyruvate, which largely escapes from the energy efficient Krebs 
cycle in the mitochondria [3]. This phenomenon, first described by Otto Warburg almost 100 years 
ago, and now known as Warburg’s effect or “aerobic glycolysis”, is considered one of the emerging 
hallmarks of cancer [4]. The clinical manifestation of altered glucose metabolism in the organism 
is diabetes mellitus, considered a risk factor for, and a consequence of, PDAC [5].  Although it is 
not known whether glucose metabolic alterations in the cancer cell, and in the entire organism, 
influence each other, it has been suggested that insulin and insulin-like growth factors play a part in 
cancer onset and progression [6,7].
Alterations in glucose metabolism at the cancer cell site
Although first described almost 100 years ago, renewed attention in the Warburg effect over the 
last few decades, has led to the definition of two main concepts: 
1. Metabolic reprogramming is a feature of cancer cells contributing to proliferation and 
metastases  [3,8];
2. Drugs targeting cancer metabolism might enhance the efficacy of chemotherapy [9]. 
In PDAC, cancer cells are dispersed within a hypovascular dense desmoplasia, which contributes 
to a hypoxic and nutrient deficient tumoral microenvironment. These features might limit the 
access of cancer cells to fuel and nutrients, indispensable for the biosynthesis of amino acids and 
nucleotides, required for cell proliferation. By reprogramming their metabolism, PDAC cells are 
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Abstract
The reprogrammed metabolism of cancer cells underlies the shift of glucose energetics from the 
highly efficient oxidative phosphorylation to the less efficient aerobic glycolysis, the Warburg 
effect. This phenomenon, with the activation of the glutamine pathway, advantages survival and 
proliferation of pancreatic ductal adenocarcinoma (PDAC) cells, which live in an adverse hypoxic 
and nutrient restricted microenvironment. In PDAC, glucose metabolic alterations occur also at 
the whole organism, Diabetes Mellitus (DM) being diagnosed in approximately 60% to 80% of 
patients.  The association between PDAC and DM is a dual face phenomenon, DM being both a risk 
factor for and a consequence of this tumor type. Data from epidemiology indicate that longstanding 
DM increases PDAC risk 1.5 to 2.0 fold, probably because of the pro-proliferative effects of 
hyperinsulinemia. By contrast early onset DM, i.e. diabetes diagnosed no more than two years 
prior to cancer diagnosis, is considered a consequence of PDAC. Secondary DM is due to complex 
interactions between tumor cells, tumor microenvironment and pancreatic endocrine cells. In this 
scenario the role of the inflammatory S100A8 calcium binding protein, matrix metalloproteinases, 
Vanin1 or amylin has been experimentally demonstrated. However, the efforts made to translate in 
the clinical practice any individual new poteantial biomarker failed, because none reached enough 
sensitivity and specificity to be considered a reliable biomarker to diagnose PDAC even in high risk 
subjects as those with new onset DM. Therefore the identification and clinical validation of new 
biomarkers remains a challenge for future studies.
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enabled to support amino acids and nucleotide biosynthesis, thus 
deriving advantage from the adverse microenvironment. In cancer 
cells glucose uptake and glycolysis are favoured by the over expression 
of the glucose transporter GLUT1 and of a series of glycolytic 
enzymes, including lactate dehydrogenase (LDH, that converts 
pyruvate into lactate), hexokinase 2 (HK2, the first rate limiting 
enzyme of glycolysis) and pyruvate kinase M2 (PKM2, the final rate 
limiting enzyme of glycolysis) [2]. Even in the presence of oxygen, 
only a minimal part of pyruvate enters mitochondrial oxidative 
phosphorylation (OXPHOS), mainly being converted to lactate; this 
is due, at least in part, to the inactivation of pyruvate dehydrogenase 
(PDH, which converts pyruvate into acetyl-CoA for the TCA cycle). 
Lactate accumulates in the microenvironment and lowers pH, which 
induces the expression of matrix metalloproteinases, mainly MMP-
2 and MMP-9 [3], while inhibiting the immune response [10], thus 
favouring the metastatic potential. Aerobic glycolysis is less efficient 
than OXPHOS in terms of energy supply: only four rather than 
36 ATP moles per mole of glucose are produced. Energy supply 
by OXPHOS in cancer cells may be supported by the glutamine 
pathway, which also supports the biosynthesis of nucleotides, lipids 
and glutathione [11]. The metabolic reprogramming of cancer cells by 
means of aerobic glycolysis and glutaminolysis, appears to be closely 
correlated with the genetic landscape of cancer cells themselves. KRAS 
activating mutations, TP53 loss of function and MYC over expression, 
frequently found in PDAC, regulate the Warburg’s effect [2,9]. It 
has recently emerged that in tumours metabolic reprogramming is 
not restricted to cancer cells: this phenomenon, also known as the 
reverse Warburg effect, also involves stromal cells, such as cancer 
associated fibroblasts (CAFs). In pseudo-hypoxyc conditions, CAFs 
produce HIF-1 alpha, which promotes glycolysis with the production 
of lactate that further reduces pH, and glutamate, which might fuel 
cancer cells. This metabolic symbiosis also occurs between cancer cells 
and cancer stem cells [3], and between cancer cells and immune cells 
[12]. Intriguingly, elsewhere we observed a reverse Warburg effect in 
myoblasts, the magnitude of lactate production being correlated with 
PDAC-associated diabetes mellitus, suggesting that there is a link 
between alterations in glucose metabolism at the cancer cell site and 
in the whole organism [13].
Alterations in Glucose Metabolism in the 
Whole Organism
Diabetes mellitus as a cause of PDAC – evidence from 
epidemiology
The association between diabetes mellitus and PDAC has been 
recognised for over 100 years. Diabetes mellitus or reduced glucose 
tolerance are diagnosed in the majority of PDAC patients, i.e. 50% 
and 30-40% of cases, respectively [14]. This high association rate 
was soon to give rise to the question as to whether diabetes mellitus 
was the cause or effect of PDAC. Epidemiological and experimental 
studies conducted to address this issue have led to the conclusion that 
diabetes mellitus is a modest risk factor for PDAC, which is rather a 
cause of diabetes mellitus. In 2005 in their meta-analysis, Huxley et 
al. [15] analysed 17 case-control and 19 cohort studies and reported 
pooled risk estimates for PDAC among diabetics of 1.94 (95% CI: 
1.53-2.46) and 1.73 (95% CI: 1.59-1.88), respectively. On considering 
studies investigating the association between PDAC and the duration 
of pre-existing diabetes mellitus, the authors reported that the shorter 
the duration of diabetes, the higher the risk of PDAC, the relative 
risk being 2.05 (95% CI: 1.87-2.25) for a duration of four years or 
less, 1.54 (95%CI: 1.31-1.81) for a duration above five and equal to 
or less than 9 years, and 1.51 (95%CI: 1.16-1.96) for a longstanding 
history of diabetes (>=10 years). The magnitude of the overall 
increase in PDAC risk among diabetics and its decreasing trend 
proportionate to the duration of diabetes has been confirmed in two 
large pooled analyses of data from US and European case control 
studies [16,17]. The increased PDAC risk associated with diabetes 
mellitus appears to be independent from geographic location [18], 
the risk estimates reported for eastern Asia being close to those of 
Europe and US [adjusted hazard ratio: 1.54 (95% CI 1.39–1.71) in 
Taiwan and 2.1 (95% CI 1.3–3.5) in Japan] [19,20]. Epidemiological 
studies exploring the inverse relationship between the duration 
of diabetes mellitus and PDAC risk agree that early onset diabetes 
mellitus is probably a manifestation of PDAC rather than a pre-
existing condition, while longstanding diabetes mellitus increases 
the risk of PDAC [15,17,18,21,22]. However, consensus has not been 
attained concerning the time limit distinguishing early onset from 
longstanding diabetes mellitus. This time limit ranges from one to 
four years across studies [15,18], although the majority of authors 
agree with a duration of less than two years in defining the early 
onset form [17,21,22]. The difficulty in defining this temporal limit 
might also depend on the following: a) when PDAC develops on a 
ground of pre-existing longstanding diabetes mellitus, the tumour 
might progressively decompensate metabolic control and, in this 
case, the switch time from non-neoplastic to neoplastic diabetes 
might be extremely difficult to define; b) PDAC arises from precursor 
lesions, such as pancreatic intraepithelial neoplasia (PanIN) or 
intraductal papillary mucinous neoplasia (IPMN), its evolution and 
progression following a stepwise model similar to that described for 
the polyp adenocarcinoma sequence in colon cancer [23]. PDAC cells 
accumulate a series of molecular aberrations. Some, namely KRAS, 
CDKN2A, TP53 and SMAD4, are highly frequent across tumours 
while others are sporadic, thus accounting for the extremely high 
molecular heterogeneity of this tumour type [24,25]. The stepwise 
accumulation of genetic defects during tumour progression might 
underlie a stepwise worsening of tumour-associated diabetes mellitus 
the progression of which might follow the evolution of the tumour, 
its clinical manifestations occurring and diagnosis being made after 
variable periods of mild hyperglycemia. This suggestion is borne out by 
Disease prevalence Biomarker Sensitivity Biomarker Specificity PPV NPV
0.00013 0.90 0.90 0.0012 0.9999
0.03 0.90 0.90 0.2177 0.9966
0.00013 0.95 0.95 0.0025 0.9999
0.03 0.95 0.95 0.3701 0.9984
0.00013 0.99 0.99 0.0129 0.9999
0.03 0.99 0.99 0.7538 0.9997
Table 1: PDAC prevalence impacts on the positive (PPV) and negative (NPV) predictive values of biomarkers.
Daniela Basso, et al. Clinics in Oncology - Pancreatic Cancer
Remedy Publications LLC., | http://clinicsinoncology.com/ 2016 | Volume 1 | Article 11233
findings from the Mayo Clinic demonstrating a progressive increase 
in blood glucose starting from 36 months prior to PDAC diagnosis 
[26], thus supporting the proposal of screening asymptomatic 
individuals using new-onset hyperglycemia and diabetes as a first 
filter to detect those at a higher risk of PDAC. However this detection 
calls for a reliable biomarker of pancreatic cancer-associated diabetes 
mellitus [27].
Longstanding diabetes mellitus preceding PDAC is not a 
single entity, but a highly complex and heterogeneous disease. The 
heterogeneity is due to differences in comorbidities, medications, 
compensation, and in some cases, exposure to diabetogenic and/or 
carcinogenetic environmental factors. The metabolic syndrome, the 
main comorbidity of diabetes mellitus to have been investigated, is 
a complex of inter-related co-existing conditions, mainly insulin 
resistance and diabetes, hypertension, dyslipidemia and obesity. 
Epidemiological studies exploring the role of diabetes mellitus as a 
risk factor for PDAC while taking other components of the metabolic 
syndrome into account have confirmed that diabetes mellitus has 
an independent role, but have also highlighted an increased body 
mass index as a risk factor for PDAC [20,28]. Co-existent metabolic 
syndrome components appear to enhance the risk of PDAC [29]. 
Available treatments for diabetes mellitus mainly include insulin 
and oral antidiabetic drugs. Since it targets hepatocytes, adipocytes 
and muscle cells, insulin is the main glucose-regulating hormone. 
However, in other normal and transformed cell types this drug has 
a relevant pro-proliferative and pro-survival effects through direct 
or indirect effects, which include enhancing of insulin-like growth 
factor I activity [6]. It is therefore more than likely that diabetes 
mellitus increases PDAC risk because of hyperinsulinemia due 
to insulin resistance and/or insulin therapy. However, although 
some epidemiological studies support the assumption that insulin 
treatment increases PDAC risk among diabetics two to fivefold 
[16,22], other studies do not [30]. In a few epidemiological studies 
focusing on patients with type 1 diabetes mellitus, invariably treated 
with insulin, PDAC risk (RR: 2.0, 95% CI: 1.37-3.01) was similar to 
that of patients with type 2 diabetes mellitus [31], thus suggesting 
that insulin treatment in case of endogenous insulin deficiency has a 
neutral effect on the risk of PDAC. The protective or carcinogenetic 
effects of oral antidiabetics is still widely debated, even if treatment 
with metformin appears to slightly decrease, while sulfonylureas 
appear to increase, PDAC risk (30). A poor glycemic control in 
diabetics might be regarded as a potentially relevant risk factor 
for PDAC since chronic hyperglycemia can induce an increased 
tumour cell proliferation and migration by enhancing the release of 
the chemokine CXCL12 from stromal pancreatic stellate cells [32]. 
Although the specific aim of these studies was not to investigate 
how poor glycemic control impacts on PDAC risk, in a population 
of male smokers fasting glucose was shown to correlate with PDAC 
risk [33], and in their dose response meta-analysis Liao et al. [34] 
found a linear dose-response relation between fasting blood glucose 
concentration and the rate of PDAC, every 0.56 mmol/L increase 
in fasting blood glucose being associated with a 14% increase in the 
rate of pancreatic cancer. Fasting glucose is, however, an imperfect 
index of the glycemic control, glycated haemoglobin (HbA1c) being 
a much more reliable tracer of long-term glucose exposure. The pre-
diagnostic levels of HbA1c are also positively correlated with PDAC 
risk with a linear trend across increasing quartiles [35]. While in type 
1 diabetes mellitus, insulin is lacking as a consequence of beta cell 
destruction, in type 2 diabetes mellitus hyperinsulinemia frequently 
occurs as a consequence of insulin resistance. Epidemiological studies 
have been conducted to investigate whether or not insulin resistance 
is the main predisposing factor for PDAC in diabetics. Stolzenberg-
Solomon et al. used the HOMA-IR formula {[fasting insulin (mIU/L) 
x fasting glucose (mmol/L)]/22.5} to estimate insulin resistance and 
their findings indicate that an increased HOMA-IR is a risk factor 
for PDAC, this risk appearing to be greater when insulin resistance 
is diagnosed more than ten years before cancer. Wolpin et al. [33] 
used plasma proinsulin levels as a marker of peripheral insulin 
resistance in their study, which confirmed that insulin resistance 
was associated with an almost 2.5-fold increase in the risk of PDAC, 
the risk being even greater (3.6-fold) when insulin resistance was 
detected more than 10 years before cancer diagnosis [35]. In their 
study, Michaud et al. provided further evidence of the role of insulin 
resistance in increasing PDAC risk. These Authors found that 
elevated post-prandial C-peptide, a fragment enzymatically released 
from proinsulin in equimolar concentrations with insulin, enhances 
the PDAC risk 4.24-fold [36]. Hyperinsulinemia should therefore be 
considered one of the factors involved in PDAC carcinogenesis, in 
line with its pro-survival and pro-metastatic effects [6,7,37]. 
Biomarker Positive/Total PDAC cases (Sensitivity)
Negative/Total diabetes cases 
(Specificity%)
Negative/Total controls 
(Specificity%)
Reference Nr.
CA 19-9 39/68 (57%) PDAC with new onset DM 1812/2295 (79%) new onset DM NA [57]
CA 19-9 43/80 (54%) PDAC with new onset DM 78/85 (92%) new onset DM 76/80 (95%) [58]
CA 19-9 47/60 (78%) PDAC with DM 42/43 (98%) Type 2 DM 29/30 (97%) [40]
Plasma IAPP 17/30 (57%) 23/23 (100%) 24/25 (96%) [59]
Plasma IAPP 22/60 (36%) PDAC with DM 8/9 (89%) 104/107 (97%) [60]
Combined blood mRNA expression of vanin 
1 (VNN1) and matrix metalloproteinase 9 
(MMP9)
23/24 (96%) PDAC with DM NA 19/25 (76%) [61]
Blood mRNA expression of MMP9 31/60 (52%) PDAC with DM 37/43 (86%) Type 2 DM 30/30 (100%) [40]
Serum cysteamine (downstream molecules 
of VNN1)
8/18 (44%) PDAC with new 
onset DM 13/15 (87%) new onset DM 15/15 (100%) [54]
Plasma adrenomedullin 16/30 (53%) PDAC with new onset DM 24/27 (89%) new onset DM 25/28 (89%) [52]
Combined serum miR-483-5p, miR-19a, 
miR-29a, miR-20a, miR-24, and miR-25
47/50 (95%) PDAC with new 
onset DM 30/50 (60%) new onset DM 30/50 (60%) [58]
Combined model with CA 19-9, 
Apolipoprotein A1 and complement C3
51/57 (90%) PDAC with DM 54/68 (80%) Chronic pancreatitis with 
DM (n=17) and Type 2 DM (n=51) NA [62]
Table 2: Proposed biomarkers for the diagnosis of PDAC in the selected population of patients with diabetes mellitus.
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Diabetes mellitus as a consequence of PDAC – clinical 
and experimental evidence
The concept that early onset diabetes mellitus is a consequence 
of PDAC is supported not only by the epidemiological observations 
described in the previous section, but also by the clinical observation 
that overt diabetes mellitus or reduced glucose tolerance is found 
in more than 60% of patients at PDAC diagnosis [38-40], and that 
diabetes mellitus ameliorates after surgical removal of the tumor 
[41,42]. This last finding, furthermore, argues against the simple 
hypothesis that pancreatic cancer-associated diabetes mellitus is due 
to cancer-related islet cells destruction and supports the hypothesis 
that PDAC induces diabetes through the release of diabetogenic 
molecules, which might cause peripheral insulin resistance and/or 
impaired insulin release from beta-cells, both of which have been 
found in PDAC patients [43-45]. Another clinical issue concerns the 
impact of diabetes mellitus on the prognosis of patients with PDAC. 
Fasting glucose levels are positively associated with the overall cancer-
related mortality [46], and survival after surgical removal of PDAC 
was shown to be significantly affected by uncontrolled longstanding 
severe hyperglycemia [47].
PDAC-associated diabetes mellitus and islet cell 
dysfunction
Several research groups, ours included, have thrown light on 
the pathophysiological mechanisms underlying PDAC-associated 
diabetes mellitus, which is due to a complex interplay between tumor 
and stromal-derived molecules, pancreatic endocrine cells and insulin 
targeted peripheral tissues/organs. The key player molecules in this 
process appear to be matrix metalloproteinases and the calcium 
binding protein, S100A8, a 10 kDa protein belonging to the family of 
S100 Ca2+ binding EF hand type proteins [48], which form homo- and 
hetero-complexes, S100A9 being the main binding partner of S100A8. 
The resulting S100A8/A9 heterodimer, also known as calprotectin, 
is normally produced and released by polymorphonuclear and 
mononuclear cells. The extracellular S100A8/A9 complex acts as a 
ligand for different receptors, including RAGE and TLR4. In PDAC, 
high S100A8 expression is found in the stromal compartment when 
tumor cells express the tumor suppressor gene SMAD4, while, when 
SMAD4 is lost, S100A8 is no longer expressed by stromal cells, but 
by cancer cells [49]. This inverse relationship between SMAD4 and 
S100A8 expression is further supported by findings made “in vitro”: 
when pancreatic cancer cells without SMAD4 expression, but with 
S100A8 expression are forced to express SMAD4 by transfection, they 
lose their ability to express S100A8 [50]. The numerous biological 
effects of S100A8 in PDAC include epithelial to mesenchymal 
transition and the SMAD4-dependent inhibition, or activation, of 
pro-survival and pro-metastatic intracellular signalling pathways 
such as NF-κB, AKT and mTOR [51]. But S100A8 can also induce the 
expression of MMP8 and of MMP9 by inflammatory mononuclear 
cells [40]. Intriguingly, S100A8 is a substrate for metalloproteinases, 
which catalyse the release of the N-terminal 14 aminoacid peptide 
from the entire molecule; this, in turn, alters intracellular calcium 
fluxes and renders beta-cells insensitive to glucose stimulation, 
leading to a reduced insulin secretion, a potential cause of PDAC-
associated diabetes mellitus [40,50]. It has also been demonstrated that 
glucose stimulated insulin secretion is reduced by adrenomedullin, 
a pluripotent hormone overexpressed in PDAC [52]. This hormone 
shares homology with amylin or islet amyloid polypeptide (IAPP), 
which is co-secreted with insulin by beta-cells at a constant ratio in 
the normal pancreas, while in the presence of PDAC-conditioned 
media, the IAPP/insulin molar ratio increases [53]. IAPP has also 
been found to reduce arginine stimulated insulin, glucagon and 
somatostatin release, and might play a part in determining islet 
dysfunction in PDAC patients [43]. It has been observed that beta-
cell proliferation impairment with apoptosis induction is dependent 
on the enzyme overexpressed in PDAC, vanin 1 (VNN1), which 
hydrolyzes pantetheine and produces Vitamin B5 and cysteamine 
[54].
PDAC-associated diabetes mellitus and impaired glucose 
metabolism in peripheral tissues
Muscle, liver and fat cells are the principal targets of insulin and 
glucagon, the two main hormones regulating glucose homeostasis. 
By binding its receptor, insulin favours glucose entry and storage 
as glycogen in target cells, while glucagon, the counter regulatory 
hormone, has the opposite effect, inducing glyogenolysis and glucose 
extrusion. The Insulin Receptor (IR), a tetrameric structure made up 
of two alpha and two beta subunits, binds insulin through its alpha 
chains and triggers intracellular signalling by the tyrosine kinase 
activity of its beta chains. The analysis of the IR signalling cascade 
in skeletal muscle tissue from PDAC patients has demonstrated that 
insulin binding, tirosin kinase activity of the IR and the content of 
the insulin receptor binding substrate 1 (IRS1) did not change with 
respect to control tissue samples, while the phosphatidylinositol 
3-kinase (PI3-K) activity, glucose transport and glycogen synthase 
activity were impaired in pancreatic cancer patients [43,45]. We 
demonstrated that pancreatic cancer cells impair glycolysis of 
both muscle and liver cells through the activity of a low molecular 
weight tumor product that favours the metabolic shift of glucose 
from oxidative phosphorylation to aerobic glycolysis (lactate 
accumulation) and, in liver cells, to triglyceride biosynthesis through 
the accumulation of the intermediate D-1,2-diacylglycerol [13,55].
Biomarkers of PDAC-associated diabetes mellitus
Experimental studies have been performed to verify the 
pathophysiology of PDAC-associated diabetes mellitus and to 
identify any potential tumor derived molecule involved in causing 
islet cell and or peripheral glucose metabolic alterations, the end 
point being to identify a biomarker able to distinguish between the 
presence or absence of PDAC in patients with new onset diabetes 
mellitus. When exploring emerging biomarkers in this setting, a 
careful consideration should be made of the disease prevalence, since 
it significantly impacts on positive and negative predictive values for 
any given combination of sensitivity and specificity of the studied 
biomarker. The prevalence of PDAC varies between unselected 
and selected populations: in the whole asymptomatic population, 
its prevalence appears almost equal to its incidence (13/100000 per 
year, 0.013%) [56], being 230 fold lower than that reported among 
the selected population of asymptomatic patients with diabetes 
mellitus (almost 3%) [57]. Based on prevalence, the positive and 
negative predictive values of a biomarker with a given sensitivity and 
specificity are reported in Table 1. PDAC prevalence impacts on the 
positive (PPV) and negative (NPV) predictive values of biomarkers. 
PDAC prevalence in the general population (0.00013) and among 
patients with new onset diabetes mellitus (0.03) were considered to 
calculate PPV and NPV of biomarkers with 90, 95 and 99% sensitivity 
and specificity. Negative predictive value (NPV): Sensitivity 
x (1-Prevalence)/Specificity (1-Prevalence) + (1-Sensitivity) x 
prevalence. Positive predictive value (PPV): Sensitivity x Prevalence/
Sensitivity x Prevalence + (1-Specificity) x (1-Prevalence) Clearly, in 
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the unselected general population, positive findings of a biomarker 
with a very high sensitivity and specificity (99%) are due to PDAC in 
about 1/100 cases, thus supporting the notion that PDAC screening 
of the general population is not recommended. By contrast, in 
selected patients, a biomarker with a sensitivity and specificity of 
95% could allow the identification of a potentially relevant number 
of cases, i.e. 37 PDAC out of 100 patients with positive results. It is 
also clear that sensitivity and specificity should be at least 90% to limit 
over-diagnosis and over-use of invasive diagnostic procedures. The 
biomarkers suggested for diagnosing PDAC in the selected population 
of patients with new-onset diabetes mellitus, include the established 
CA 19-9 marker as well as emerging new potential biomarkers, such 
as proteins, peptides, microRNA and mRNA, the detailed description 
of which also in terms of sensitivity and specificity is reported in 
Table 2. Overall none of the proposed biomarkers is superior to the 
established marker CA 19-9 in terms of sensitivity and specificity 
for PDAC diagnosis in patients with diabetes mellitus. Moreover, 
since none attain a sensitivity and specificity of at least 90%, their use 
cannot be supported in clinical practice.
In conclusion, the efforts made to translate in the clinical practice 
new potential biomarkers of PDAC-associated diabetes mellitus 
have failed, due to low sensitivity and specificity. Therefore the 
identification and clinical validation of new biomarkers remains a 
challenge for future studies.
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